These abstracts are selected by the Young Urologic Oncologists Committee prior to the Winter Annual Meetings. The Committee selects the top three to six best abstracts submitted to be presented at the meeting by a resident or fellow. The awardees present their abstracts during the scientific program at the meeting.
2022
Kyle M. Rose, MD
Neoadjuvant Platinum-Based Chemotherapy for Metastatic Penile Squamous Cell Carcinoma (PSCC): An International, Multicenter, Real-World Study
2022
Benjamin Pockros, MD
Out-Of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Part D Plan: An Online Tool Could Save Patients Thousands of Dollars
2022
Kathryn Hacker Gessner, MD
Decisional Conflict Among Patients Newly Diagnosed With Clinical T1 Renal Masses
2022
Laura Bukavina, MD, MPH
Global Meta-Analysis of Urine Microbiome: Colonization of PAH-Degrading Bacteria Among Bladder Cancer Patients
2021
Patrick Hensley, MD
IMMUNOHISTOCHEMICAL SIGNATURES PREDICT BLADDER CANCER RESPONSE TO NEOADJUVANT CHEMOTHERAPY
2021
Song Jiang, MD, PhD
TARGETED EXON-SEQUENCING OF MATCHED PRE- AND POST-TREATMENT TUMOR SAMPLES FROM PATIENTS UNDERGOING BCG THERAPY REVEALS CONCORDANCE OF ACTIONABLE GENETIC ALTERATIONS
2021
Robert Parker
PREOPERATIVE GUIDED IMAGERY IN PATIENTS UNDERGOING MAJOR UROLOGIC SURGERY: A RANDOMIZED CONTROLLED TRIAL
2020
Neil Mendhiratta, MD
Winner
Decisional regret & financial toxicity among patients with benign renal masses
2020
Vikram Narayan, MD
Winner
Anti-adenoviral antibody response positively correlates with efficacy of nadofaragene firadenovec for HG BCG unresponsive NMIBC
2020
Jorge Daza, MD
Runner-Up
Gene expression analysis of the bladder tumor microenvironment reveals a novel B cell signature in NMIBC patients after treatment with M. bovis BCG
2020
Marybeth Hall, MD
Runner-Up
Association Between Disease Indication And Steroid Use And Mineralocorticoid-Related Toxicity Of Abiraterone Acetate In Patients With Advanced Prostate Cancer: A Meta-Analysis Of Randomized Control Trials
2020
Vidit Sharma, MD
Runner-Up
Obesity Explains Significant Statewide Variation In Renal Parenchymal Tumor Incidence In The United States
2020
Udit Singhal, MD
Runner-Up
Determining the impact of genomic classifier testing on patient-reported quality of life in men at high-risk of post-prostatectomy recurrence: results from G-MINOR randomized clinical trial
2019
Eric C. Umbreit, MD
ORIGIN OF GERM CELL TUMORS: SOMATIC TRANSFORMATION AND THE PRESENCE OF CANCER STEM-LIKE CELLS IN TERATOMA
2019
Shaheen Alanee, MD, MPH, MBA
PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUÉRIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN HIGH GRADE NONMUSCLE INVASIVE BLADDER CANCER
2019
Kathryn Hacker Gessner, MD, PhD
IMPLEMENTATION OF STANDARD OPIOID PRESCRIBING SCHEDULES FOLLOWING UROLOGIC SURGERIES REDUCES OPIOID PRESCRIPTIONS WITHOUT CHANGE IN PATIENT REPORTED OUTCOMES
2019
Tullika Garg, MD, MPH
RISK OF MULTIPLE LEVELS OF RECURRENCE AND PROGRESSION AFTER INITIAL DIAGNOSIS OF NON-MUSCLE INVASIVE BLADDER CANCER IN A MULTI-SITE, COMMUNITY-BASED COHORT
2018
Sigrid Carlsson, MD, PhD, MPH
Long-Term Outcomes of active surveillance for prostate cancer – the Memorial Sloan Kettering Cancer Center experience
2018
Kathryn Hacker, MD, PhD
Post-Operative Opioid Prescribing In Urology: Are We Contributing To The National Crisis?
2018
Vignesh T. Packiam, MD
CG0070, An Oncolytic Adenovirus, for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): 18-Month Follow-Up From a Multicenter Phase II Trial
2017
Carissa Ellen Chu, MD
PROSTATE CANCER INCIDENCE, TREATMENT TRENDS, AND SURVIVAL AMONG AMERICAN INDIANS AND ALASKAN NATIVES IN THE UNITED STATES
2017
Parth K. Modi, MD
PROSTATE CANCER TREATMENT VARIATION IN ACCOUNTABLE CARE ORGANIZATIONS
2017
Chad Reichard, MD
CT SCAN HAS HIGH RATE OF INCIDENTAL FINDINGS AND LOW CLINICAL UTILITY IN A COHORT OF HIGH RISK PROSTATE CANCER PATIENTS STAGED WITH 99MTC BONE SCAN AND PELVIC MR
2016
Brandon Manley, MD
Characterizing Recurrent and Lethal Small Renal Masses in Clear Cell Renal Cell Carcinoma Using Recurrent Somatic Mutations
2016
Peter Chang, MD, MPH
Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The Prost-QA/RP2 Consortium
2016
Simpa S. Salami, MD, MPH
Prevalence and Prognostic Significance of Circulating Tumor Cells (CTC) in Clinically Localized Prostate Cancer
2015
Roland Seiler, MD
Prediction of Lymph Node Metastases in Bladder Cancer Using Gene Expression Signatures of Primary Tumors
2015
Kelvin Moses, MD, PhD
Patterns of PSA Screening Among Low Income African-American and Caucasian Men: Data from the Southern Community Cohort Study
2015
Richard Matulewicz, MD, MS
Is Poor Adherence to Guidelines Further Evidence of the Need for Centralization of Penile Cancer Care?
2014
Arnold Chin, MD, PhD
Role of RIP2 in Development of Tumor-Infiltrating MDSCS and Bladder Cancer Metastasis
2014
Ahmed Haddad, MD
Preoperative Multivariable Prognostic Models for Prediction of Survival and Major Complications Following Surgical Resection of Renal Cell Carcinoma with Suprahepatic Caval Tumor Thrombus
2014
Timothy Daskivich, MD, MSHPM
An Age-Adjusted Comorbidity Index for Prediction of Long-Term, Other-Cause Mortality in Men with Prostate Cancer
2014
Nicholas Cost, MD
Referral Patterns in Testicular Cancer: Do They Impact Oncologic Outcomes?
2013
Florian Schroeck, MD
The Impact of Technology Diffusion on Treatment for Prostate Cancer
2013
M. Minhaj Siddiqui, MD
Utilization of a Prostate MRI Nomogram for Prediction of Biopsy Gleason Score
2013
John Sullivan, MD
A Single Center Validation Analysis of Prostate Cancer Risk Loci from Published GWAs: Association with PSA Levels, Prostate Cancer Progression and Mortality
2012
Florian Schroeck, MD
Large Regional Variation in Quality of Prostate Cancer Care Highlights Opportunity for Quality Improvement
2012
Adam Feldman, MD
To Biopsy or Not to Biopsy: Results of 1000 Renal Mass Biopsies at a Single Institution
2012
Jeffrey Bassett, MD
Introduction of a Tobacco-Screening Initiative for Those with or at Risk for Bladder Cancer: The Case of a High Volume Urology Clinic
2011
Uri Lindner, MD
MR-Guided Laser Focal Therapy for Low - Intermediate Risk Localized Prostate Cancer
2011
Brian Schuch, MD
Adrenal Nodular Hyperplasia as Part of the Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Phenotype
2011
Kenneth Nepple, MD
Hospital Readmission After Radical Cystectomy for Bladder Cancer: Results of a Population-Based Analysis from the California State Inpatient Database
2010
Jose Karam, MD
Development and Characterization of Tumor Models from Patients with Renal Cell Carcinoma
2010
Amit Gupta, MD
Radical Cystectomy and Urinary Diversion is Associated with a Greater Risk of Fractures in Patients with Bladder Cancer
2010
David Margel, MD
Oral Contraceptive Use is Associated with Prostate Cancer: An Ecologic Study
2009
Daniel A. Barocas, MD
The Association Between Oxidative Stress and Prostate Cancer Risk in Men Undergoing Prostate Biopsy
2009
Shahrokh Shariat, MD
HER2 Expression Status Provides Independent Prognostic Information in Patients with Urothelial Carcinoma of the Bladder
2009
Thomas Sanford, MD
Molecular Sub-Classification of Renal Epithelial Neoplasms
2008
Jose Karam, MD
Upregulation of TRAG3 (Taxol Resistance Associated Gene 3) is Associated with Advanced Bladder Cancer (BCA)
2008
Kiranpreet Khuran, MD
Comparison of Primary and Metastatic to Lymph Node Cell Lines from the Same Patients
2008
Timothy A. Masterson, MD
Clinical Outcomes in Clinical Stage III NSGCT Patients who Achieve a Complete Radiographic Response to Chemotherapy at the Site of Extra-Retroperitoneal Disease
2007
Brett Carver, MD
Aberrant ERG Expression is a Critical and Causal Event in Prostate Tumorigenesis
2007
John Davis, MD
Training Multiple Urologic Oncology Fellows in Robotic-Assisted Laparoscopic Prostatectomy
2007
Boris Hadaschik, MD
Intravesical Therapy of High Grade Bladder Cancer with HTI-286
2006
Surena Matin, MD
The Natural History of Residual and Recurrent Disease Following Renal Ablative Therapy: A Multi-Institutional Study
2006
Jim Hu, MD, MPH
Perioperative Quality Care Indicators of Retropubic, Laparoscopic, and Robotic Prostatectomy: Results from a National, Multi-Center, Prospective Cohort
2006
Robert Nam, MD, MSc
Genome-Wide Association Study for Prostate Cancer Using the Affymetrix 10k Genechip and Evaluation of Susceptibility Genes for Prostate Cancer in a Clinical Setting